NeuroTrauma Sciences, LLC
NeuroTrauma Sciences (NTS), founded in 2016, is a clinical stage biopharmaceutical company focused on improving the lives of stroke patients by developing neuroprotective therapeutics for stroke and other CNS injuries. The company is advancing a pipeline of therapeutic candidates targeting ischemic stroke, traumatic brain injury, and other neurological conditions, with a mission to address high unmet medical needs and improve patient outcomes.
Industries
Nr. of Employees
small (1-50)
NeuroTrauma Sciences, LLC
Alpharetta, Georgia, United States, North America
Products
Investigational water‑soluble neurosteroid prodrug (intravenous candidate)
A water-soluble prodrug developed for intravenous administration that is converted in plasma to an active neuroactive steroid with CNS exposure and multi-target receptor activity intended to reduce inflammation, edema, and cell death after acute brain injury.
Next-generation parenteral neuroactive candidate (subcutaneous/intramuscular)
A development-stage parenteral candidate intended for subcutaneous or intramuscular delivery aimed at expanded indications and alternative routes of administration for acute and chronic stroke.
Investigational water‑soluble neurosteroid prodrug (intravenous candidate)
A water-soluble prodrug developed for intravenous administration that is converted in plasma to an active neuroactive steroid with CNS exposure and multi-target receptor activity intended to reduce inflammation, edema, and cell death after acute brain injury.
Next-generation parenteral neuroactive candidate (subcutaneous/intramuscular)
A development-stage parenteral candidate intended for subcutaneous or intramuscular delivery aimed at expanded indications and alternative routes of administration for acute and chronic stroke.
Services
Partnerships for early-stage asset evaluation
Evaluation and co-development of early-stage assets and novel mechanisms for treating stroke and other CNS injuries via research collaborations and licensing discussions.
Support for observational clinical research and consortium projects
Financial and research support for large observational studies and data consortia aimed at biomarker validation, improved patient classification, and identification of effective clinical care practices.
Partnerships for early-stage asset evaluation
Evaluation and co-development of early-stage assets and novel mechanisms for treating stroke and other CNS injuries via research collaborations and licensing discussions.
Support for observational clinical research and consortium projects
Financial and research support for large observational studies and data consortia aimed at biomarker validation, improved patient classification, and identification of effective clinical care practices.
Expertise Areas
- Neuroprotective drug development
- Preclinical ischemic stroke modeling
- Clinical trial design and execution for CNS indications
- Regulatory strategy and IND preparation
Key Technologies
- Prodrug design for central nervous system delivery
- Intravenous and parenteral (SC/IM) formulation
- Transient and embolic middle cerebral artery occlusion rodent models (tMCAO, eMCAO)
- Behavioral and functional neuroassays (mNSS, foot fault, adhesive tape removal)